Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Uprosertib with Dabrafenib and Trametinib in BRAF Mutant Cancer
NCT01902173Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2013
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of uprosertib in solid tumor and melanoma, sponsored by National Cancer Institute. Primary endpoints: Maximum-tolerated Dose and Objective Response Rate up to 3 years. Started Oct 2013; status: completed.
02
Drugs
uprosertib
03
Conditions
solid tumormelanoma
Beyond the preview
Go deeper on NCT01902173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01902173.